Fisher Asset Management LLC Buys 4,987 Shares of United Therapeutics Corporation $UTHR

Fisher Asset Management LLC boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 26.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,580 shares of the biotechnology company’s stock after purchasing an additional 4,987 shares during the quarter. Fisher Asset Management LLC owned about 0.05% of United Therapeutics worth $9,885,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. AXQ Capital LP increased its holdings in shares of United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after acquiring an additional 3,235 shares in the last quarter. AE Wealth Management LLC raised its holdings in United Therapeutics by 396.3% during the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after buying an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC raised its holdings in United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after buying an additional 2,975 shares during the last quarter. Optimize Financial Inc bought a new position in shares of United Therapeutics in the third quarter valued at $444,000. Finally, Simplify Asset Management Inc. acquired a new position in shares of United Therapeutics during the third quarter valued at about $8,351,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Down 1.7%

United Therapeutics stock opened at $490.21 on Thursday. The firm has a 50 day moving average price of $483.67 and a 200-day moving average price of $450.90. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $537.19. The company has a market capitalization of $21.49 billion, a P/E ratio of 17.57, a P/E/G ratio of 1.79 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the prior year, the business earned $6.19 earnings per share. United Therapeutics’s revenue for the quarter was up 7.4% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the completion of the transaction, the chief financial officer owned 8,142 shares of the company’s stock, valued at $3,896,761.20. The trade was a 72.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 356,454 shares of company stock valued at $172,894,963 in the last quarter. 10.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

UTHR has been the topic of a number of analyst reports. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Wells Fargo & Company increased their price objective on United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 26th. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $533.55.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.